Is This the End of the Cisplatin Eligibility Era in Muscle-invasive Bladder Cancer? Letter in reference to: Matthew D. Galsky, Begoña P. Valderrama, Marco Maruzzo, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N Engl J Med 2026;395:338–48. doi:10.1056/NEJMoa2601486; and Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011;12:211–214. doi:10.1016/S1470-2045(10)70275-8

Study limitation reported by the research below: “The referenced trial (Galsky et al., NEJM 2026) was published in January 2026; this letter responds to it in September 2026—the full trial data are not reproduced here and should be reviewed independently.”